Home / Therapies / Devices / Terry Gregg, CEO, Dexcom: The Increasing Use of CGM

Terry Gregg, CEO, Dexcom: The Increasing Use of CGM


Terry Gregg, CEO, Dexcom, discusses the current landscape of reimbursement for CGM technology. Although insurance companies were initially slow to catch on for approving CGM devices for type 1’s, there has been a shift and approvals seem to be improving. He is also sees the overall market increasing as more type 2’s are diagnosed, the cost of oral agents keeps going up, and the continued improvement of monitoring devices….


More videos with Terry Gregg:


Terry H. Gregg is CEO of Dexcom, Inc., first joining the Dexcom Board of Directors in 2005 and subsequently appointed President and CEO in 2007 and CEO in 2011.

In 2002 he retired as President of Medtronic MiniMed, a world leader in diabetes management systems. He became President and Chief Operating Officer of MiniMed, Inc. in 1996 and was instrumental in Medtronic’s $3.4 billion acquisition of MiniMed in 2001. He also served in executive positions with Smith and Nephew and Allergan, Inc.

Mr. Gregg served as the 2003-2004 Chair of the Research Foundation Board of the American Diabetes Association. In 2010, Mr. Gregg and his wife were recognized by the Juvenile Diabetes Research Foundation (JDRF) with one of it’s highest honors, the 2010 Angel Award. Most recently, Mr. Gregg was honored as one of the San Diego regional finalists for the Ernst and Young Entrepreneur of the Year Award 2011 and named by MassDevice.com, one of 28 chief executives whom exemplify cutting-edge leadership and innovative thinking in the medical device industry, as its inaugural CEO Class of 2011.

Mr. Gregg currently serves on several advisory boards, including the Scripps Translational Science Institute.

Mr. Gregg received a Bachelor of Science degree from Colorado State University in 1971.